Failure of pentoxifylline for end-stage peripheral vascular disease.

Abstract

In this trial of pentoxifylline, 15 patients with end-stage peripheral vascular disease had symptoms severe enough to warrant operation, but surgery was contraindicated because of anatomically noncorrectable disease, serious medical problems, or refusal. Their mean age was sixty-six years. Each patient received oral pentoxifylline, 400 mg tid, for twelve weeks. Pentoxifylline had no measurable clinical benefit in 14 of the patients. In addition, the authors noted an increased incidence of symptomatic coronary artery insufficiency during the trial period that may or may not have been drug related.

• Authors: R G Loyd, G W Prian, H Gomez, J Laub, G H Mertz
• Journal: Angiology (Angiology) Vol. 38 Issue 4 Pg. 304-8 (Apr 1987) ISSN: 0003-3197 [Print] United States
• PMID: 3578918 (Publication Type: Journal Article)

Chemical References

• Theobromine
• Pentoxifylline

Topics

• Aged
• Aged, 80 and over
• Arterial Occlusive Diseases (drug therapy)
• Coronary Disease (chemically induced)
• Humans
• Intermittent Claudication (drug therapy)
• Male
• Middle Aged
• Pentoxifylline (adverse effects, therapeutic use)
• Theobromine (analogs & derivatives)